GlassScriptPhysician profile
Michael R Shohet
NPI 1942260815
$2,740.20
in general payments reported to CMS, 2019-2025
26 companies · $958 in 2025
The $958 reported for 2025 was more than what 81% of Otolaryngology/Facial Plastic Surgery providers received nationally (typical 2025 total: $305).
See the full distribution for Otolaryngology/Facial Plastic Surgery
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $798 · 2020: $144 · 2021: $248 · 2022: $122 · 2023: $202 · 2024: $269 · 2025: $958.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,429.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,429.21 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $575.56 | 2019-2025 | Nucala, Trelegy Ellipta, Arexvy |
| Genzyme Corporation | $358.11 | 2019-2025 | |
| Novartis Pharmaceuticals Corporation | $284.96 | 2022-2025 | |
| Aerin Medical INC. | $215.32 | 2019 | |
| Spirair, INC. | $190.20 | 2025 | |
| Intersect Ent, INC. | $123.56 | 2019 | |
| Acclarent, INC | $120.41 | 2019-2021 | |
| Grifols USA, LLC | $110.81 | 2023-2025 | Xembify |
| Ionis Pharmaceuticals, INC. | $87.48 | 2025 | Dawnzera |
| Csl Behring | $77.63 | 2023-2025 | Hizentra, Haegarda |
| Medtronic USA, INC. | $66.17 | 2019-2020 | |
| Regeneron Healthcare Solutions, INC. | $63.87 | 2019 | |
| Alk-Abello, INC | $56.09 | 2019 | |
| Optinose US, INC. | $54.64 | 2019-2020 | |
| Blueprint Medicines Corporation | $52.12 | 2024-2025 | Ayvakit |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Kaleo, INC. | $41.64 | 2023 | Auvi-Q |
| Takeda Pharmaceuticals U.S.A., INC. | $38.36 | 2020-2025 | Cuvitru |
| Teva Pharmaceuticals USA, INC. | $36.59 | 2020 | |
| Biocryst US Sales Co., LLC | $32.81 | 2022-2023 | Orladeyo |
| Inspire Medical Systems, INC. | $29.22 | 2025 | Inspire |
| Octapharma USA, INC. | $25.62 | 2025 | Panzyga |
| Medtronic, INC. | $24.79 | 2025 | Propel |
| Cycle Pharmaceuticals INC | $23.63 | 2025 | Sajazir |
| Shire North American Group INC | $17.26 | 2019 | |
| Hikma Pharmaceuticals USA | $16.83 | 2024 | Ryaltris |
| Stryker Corporation | $16.52 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Shohet listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.